Anti-NECAB3 monoclonal antibody Made to order

Nek2 is a mammalian protein kinase structurally homologous to Aspergillus NIMA. We previously observed that the Nek2 protein was localized in multiple sites within a cell in a cell cycle stage-specific manner. Such dynamic behavior of Nek2 allowed us to propose that Nek2 may be a mitotic regulator that is involved in diverse cell cycle events. To better understand the cellular processes in which Nek2 participates, we carried out yeast two-hybrid screening and isolated Nek2-Interacting Protein 1 (NIP1), which has been also named as XB51 and NECAB3. Physical interactions of Nek2 with NIP1 were confirmed. In fact, Nek2 can phosphorylate NIP1 in vivo. Immumostaining experiments revealed that NIP I is a Golgi protein. These results propose a possible involvement of Nek2 in biological processes of the Golgi body, perhaps in relation to the inheritance of Golgi during mitosis or to cell cycle stage-specific regulation of exocytosis. (C) 2003 Elsevier Inc. All rights reserved.

Non-small cell lung cancer (NSCLC) represents for approximately 85% of all lung cancers, which is the most common cancer worldwide. Tumor-associated macrophages (TAM) are crucial for tumor progression, which was widely believed to be mediated by long non-coding RNAs (LncRNAs). We aimed to explore the effect of one LncRNA, GNAS-AS1, in TAM-associated NSCLC progression. Relative mRNA levels were determined by qRT-PCR. Western blot and ELISA were used to detect protein levels. Proliferation in vitro was assessed by MTT and clone formation assays. Migration and invasion of cell lines were evaluated by transwell-based assays. Interaction between molecules was detected by luciferase report assay. GNAS-AS1 expression was dramatically enhanced in TAM, NSCLC cell lines, and clinical tumor tissues, and negatively correlated with overall survival of NSCLC patients. GNAS-AS1 promoted macrophage M2 polarization and NSCLC cell progression via directly inhibiting miR-4319, which could target N-terminal EF-hand calcium binding protein 3 (NECAB3) to inhibit its expression. GNAS-AS1/miR-4319/NECAB3 axis promotes tumor progression of NSCLC by altering macrophage polarization. This novel mechanism may provide potential strategy for NSCLC treatment.